Monoclonal antibody · Antagonist of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by OncoC4
Phase 3Most advanced trial
1Registered trials
What is Gotistobart?
Gotistobart is a humanized, pH-sensitive IgG1 monoclonal antibody that binds CTLA-4 on T cells, blocking CTLA-4-mediated suppression of T-cell activation. It dissociates from CTLA-4 at low pH, which is studied for selective regulatory T-cell depletion within tumors. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.